Laurence Albiges, M.D., Ph.D., Vice-Chair Medical Oncology Department at Gustave Roussy. In this video, she speaks about the ASCO GU 2022 abstract – CheckMate -214 (Abstracts #307 & #352): Follow-up results showing meaningful survival benefits with Opdivo plus Yervoy amongst intermediate- and poor-risk RCC patients with sarcomatoid features "“ a population with poor prognosis and limited therapeutic options – as well as quality of life improvements amongst the all-randomized population.
Podcast Laurence Albiges, MD @AlbigesL @GustaveRoussy #ASCOGU22 #GU22 #RCC Phase III CheckMate 214 Trial
